According to FutureWise analysis the market for hemophilia treatment in 2023 is US$ 12.29 billion, and is expected to reach US$ 18.46 billion by 2031 at a CAGR of 5.22%.
Haemophilia is an inherited medical condition that affects how blood clots, causing irregular clotting. After an injury, surgery, or dental work leads to spontaneous and profuse bleeding, easy bruising, and oozing. It is brought on by a congenital deficit of a coagulation factor, which inhibits blood clotting since there aren't enough blood-clotting proteins. Treatment options include prescription drugs, hormone replacement treatment, and plasma or clotting factor injections. The goal of treatment is to prevent problems and replace lost proteins.
Haemophilia A patient will bleed more than usual following an operation, surgery, or dental procedure. A lack of a protein called factor VIII leads to hemophilia A. Replacement therapy is the most typical treatment for clotting factor VIII injection or drip into a vein. According to the National Centre for Biotechnology Information (NCBI), emicizumab is now the only approved nonfactor medication that treats venous access problems, recurrent bleeding, and other problems. Additionally, this course of treatment is advised for individuals taking inhibitors and getting surgery to stop bleeding. Following recent developments, these novel medications demonstrate potential hemostatic properties and significantly reduce bleeding episodes in hemophilia patients, whether they use inhibitors or not. The increased prevalence of hemophilia globally would be a key factor in expanding the market's growth rate.
FutureWise Market Research has published a report that provides an insightful analysis of hemophilia treatment market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, the hemophilia treatment market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.